Novo Nordisk can celebrate obesity drug Wegovy, which is built on the GLP-1 analog semaglutide, as it has demonstrated a significant and sustained weight loss of 15.2 percent in a two-year study.
"What is interesting to me is to see that the weight loss we have reported so far, which has been around 15-17 percent, is the same we're seeing after two years," Executive Vice President, Development at Novo Nordisk Martin Holst tells MedWatch about the results from the company's Step 5 study, which were presented last week during this year's Obesity Week.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Quality System Manager 
Communications Consultant 
Clinical Project Manager 
Senior IT Network Engineer 
Senior Project Manager (GMP - Life Science) 
Cell Culture Scientist/Senior Scientist 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Scientific Writer 
Director for innovative pre-clinical testing unit 
Key Account Manager, Europe and Asia 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Clinical Trial Manager for development of in vitro diagnostics 
Director Global Engineering 
IRT Manager, Clinical Drug Supply